A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay

Biochemical Pharmacology

Volumn 67, Issue 2, 2004, Pages 227-234

  Asai, Akira ^a   Tsujita, Tetsuya ^a   Sharma, Sreenath V ^a   Yamashita, Yoshinori ^a   Akinaga, Shiro ^a   Funakoshi, Minoru ^b   Kobayashi, Hideki ^b   Mizukami, Tamio ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Belactosin; CDK; Cyclin; Inhibitor; Lactacystin; Proteasome

Indexed keywords

BELACTOSIN A; BELACTOSIN B; BELACTOSIN C; BELACTOSIN DERIVATIVE; CHYMOTRYPSIN; KF 33955; KF 44504; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASSAY; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROPHOBICITY; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOMYCES; STRUCTURE ACTIVITY RELATION; UBIQUITINATION; YEAST;

EID: 1642276251     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.08.035     Document Type: Article

References (27)

1. Sherr C.J. Cancer cell cycle. Science. 274:1996;1672-1677.
2. Sherr C.J., Roberts M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1999;1501-1511.
3. Mejer L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol. 6:1996;393-397.
4. King R.W., Deshaies R.J., Peters J.M., Kirschner M.W. How proteolysis drives the cell cycle. Science. 274:1996;1652-1659.
5. Spataro V., Norbury C., Harris A.L. The ubiquitin-proteasome pathway in cancer. Br. J. Cancer. 77:1998;448-455.
6. DeMartino G.N., Slaughter C.A. The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem. 274:1999;22123-22126.
7. Lee D.H., Goldberg A.L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8:1998;397-403.
8. Omura S., Matszaki K., Fujimoto T., Kosuge K., Furuya T., Fujita S., Nakagawa A. Lactacystion, a novel microbial metabolite induces neuritogenesis of neuroblastoma cells. J. Antibiot. 44:1991;113-118.
9. Fenteany G., Standaert R.F., Reichard G.A., Corey E.J., Schreiber S.L. A β-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc. Natl. Acad. Sci. U.S.A. 91:1994;3358-3362.
10. Fenteany G., Standaert R.F., Lane W.S., Choi S., Corey E.J., Schreiber S.L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 268:1995;526-531.
11. Dick L.R., Cruikshank A.A., Grenier L., Melandri F.D., Nunes S.L., Stein R.L. Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin β-lactone. J. Biol. Chem. 271:1996;7273-7276.
12. Adams J., Palombella V.J., Elliott P.J. Proteasome inhibition: a new strategy in cancer treatment. Invest. New Drugs. 18:2000;109-121.
13. Murray R.Z., Norbury C. Proteasome inhibitors as anti-cancer agents. Anticancer Drugs. 11:2000;407-417.
14. Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazarus D.D., Maas J., Pien C.S., Prakash S., Elliott P.J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59:1999;2615-2622.
15. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr. Opin. Chem. Biol. 4:2002;493-500.
16. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol. Med. 8:2002;S49-S54.
17. Funakoshi M., Sikder H., Ebihara K., Irie K., Sugimoto K., Matsumoto K., Hunt T., Kobayashi H. Xenopus cyclin A1 can associate with Cdc28 in budding yeast, causing cell-cycle arrest with an abnormal distribution of nuclear DNA. Genes Cells. 2:1997;329-343.
18. Asai A., Hasegawa A., Ochiai K., Yamashita Y., Mizukami T. Belactosin A, a novel antitumor antibiotic acting on cyclin/CDK mediated cell cycle regulation, produced by Streptomyces sp. J. Antibiot. 53:2000;81-83.
19. Tsukuda E., Tanaka T., Ochiai K., Kondo H., Yoshida M., Agatsuma T., Saitoh Y., Teshiba S., Matsuda Y. EI-1507-1 and -2, novel interleukin-1 beta converting enzyme inhibitors produced by Streptomyces sp. E-1507. J. Antibiot. 49:1996;333-339.
20. Hara M., Akasaka K., Akinaga S., Okabe M., Nakano H., Gomez R., Wood D., Uh M., Tamanoi F. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc. Natl. Acad. Sci. U.S.A. 90:1993;2281-2285.
21. Meng L., Mohan R., Kwok B.H., Elofsson M., Sin N., Crews C.M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. U.S.A. 96:1999;10403-10408.
22. Princiotta M.F., Schubert U., Chen W., Bennink J.R., Myung J., Crews C.M., Yewdell J.W. Cells adapted to the proteasome inhibitor 4-hydroxy-5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival. Proc. Natl. Acad. Sci. U.S.A. 98:2001;513-518.
23. Verma R., Annan R.S., Huddleston M.J., Carr S.A., Reynard G., Deshaies R.J. Phosphorylation of Sic1p by G1 Cdk required for its degradation and entry into S phase. Science. 278:1997;455-460.
24. Maki C.G., Huibregtse J.M., Howley P.M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56:1996;2649-2654.
25. Pagano M., Tam S.W., Theodoras A.M., Romero-Beer P., Del Sal G., Chau V., Yew R., Draetta G., Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:1995;682-685.
26. Loda M., Cukor B., Tam S.W., Lavin P., Fiorentino M., Draetta G.F., Jessup J.M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3:1997;231-234.
27. Hanada M., Sugawara K., Kaneta K., Toda S., Nishiyama Y., Tomita K., Yamamoto H., Konishi M., Oki T. Epoxomicin, a new antitumor agent of microbial origin. J. Antibiot. 45:1992;46-52.